Search

Your search keyword '"Trastorns limfoproliferatius"' showing total 2 results
Start Over Descriptor "Trastorns limfoproliferatius"
2 results on '"Trastorns limfoproliferatius"'

1. B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection

Author

Maria Stefania Infante, Jon Salmanton-García, Ana Fernández-Cruz, Francesco Marchesi, Ozren Jaksic, Barbora Weinbergerová, Caroline Besson, Rafael F. Duarte, Federico Itri, Toni Valković, Tomáš Szotkovski, Alessandro Busca, Anna Guidetti, Andreas Glenthøj, Graham P. Collins, Valentina Bonuomo, Uluhan Sili, Guldane Cengiz Seval, Marina Machado, Raul Cordoba, Ola Blennow, Ghaith Abu-Zeinah, Sylvain Lamure, Austin Kulasekararaj, Iker Falces-Romero, Chiara Cattaneo, Jaap Van Doesum, Klára Piukovics, Ali S. Omrani, Gabriele Magliano, Marie-Pierre Ledoux, Cristina de Ramon, Alba Cabirta, Luisa Verga, Alberto López-García, Maria Gomes Da Silva, Zlate Stojanoski, Stef Meers, Tobias Lahmer, Sonia Martín-Pérez, Julio Dávila-Vals, Jens Van Praet, Michail Samarkos, Yavuz M. Bilgin, Linda Katharina Karlsson, Josip Batinić, Anna Nordlander, Martin Schönlein, Martin Hoenigl, Zdeněk Ráčil, Miloš Mladenović, Michaela Hanakova, Giovanni Paolo Maria Zambrotta, Nick De Jonge, Tatjana Adžić-Vukičević, Raquel Nunes-Rodrigues, Lucia Prezioso, Milan Navrátil, Monia Marchetti, Annarosa Cuccaro, Maria Calbacho, Antonio Giordano, Oliver A. Cornely, José-Ángel Hernández-Rivas, Livio Pagano, Infante M. S. , Salmanton-García J., Fernández-Cruz A., Marchesi F., Jaksic O., Weinbergerová B., Besson C., Duarte R. F. , Itri F., Valković T., et al., Institut Català de la Salut, [Infante MS] Hematology Deparment, Hospital Universitario Infanta Leonor, Madrid, Spain. [Salmanton-García J] Faculty of Medicine and University Hospital Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany. Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), University of Cologne, Cologne, Germany. [Fernández-Cruz A] Hospital Universitario Puerta de Hierro, Majadahonda, Spain. [Marchesi F] Hematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy. [Jaksic O] Department of Hematology, University Hospital Dubrava, Zagreb, Croatia. [Weinbergerová B] Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czechia. [Cabirta A] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus, Gilead Sciences, and Hematology

Subjects
Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Internal Diseases, Cancer Research, SARS-CoV-2, chronic lymphocytic leukemia (CLL), immune system COVID19, infection risk, lymphoproliferative diseases (LPD), non-Hodgkin lymphoma (NHL), targeted drugs, Sağlık Bilimleri, COVID-19 (Malaltia), İç Hastalıkları, Clinical Medicine (MED), BİYOKİMYA VE MOLEKÜLER BİYOLOJİ, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Medicine and Health Sciences, IDELALISIB, Klinik Tıp (MED), 03.02. Klinikai orvostan, IBRUTINIB, BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina, Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders [DISEASES], RNA COVID-19 VACCINE, BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Oncology, Klinik Tıp, OBINUTUZUMAB, CHALLENGES, Temel Bilimler, Life Sciences, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Onkoloji, ddc, Tıp, MOLECULAR BIOLOGY & GENETICS, Oncology, CHLORAMBUCIL, Medicine, ONKOLOJİ, Natural Sciences, BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Infektologija, Life Sciences & Biomedicine, BIOCHEMISTRY & MOLECULAR BIOLOGY, Sitogenetik, Life Sciences (LIFE), Molecular Biology and Genetics, Enquestes, Yaşam Bilimleri, Health Sciences, Trastorns limfoproliferatius, Cytogenetic, RITUXIMAB, BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine, Moleküler Biyoloji ve Genetik, Science & Technology, Internal Medicine Sciences, CHRONIC LYMPHOCYTIC-LEUKEMIA, técnicas de investigación::métodos epidemiológicos::recopilación de datos::encuestas y cuestionarios [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Dahili Tıp Bilimleri, CLINICAL MEDICINE, BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Infectology, enfermedades hematológicas y linfáticas::enfermedades linfáticas::trastornos linfoproliferativos [ENFERMEDADES], ONCOLOGY, EFFICACY, Settore MED/15 - MALATTIE DEL SANGUE, Yaşam Bilimleri (LIFE), BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Onkologija, Kanser Araştırmaları
Abstract

Patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin Lymphoma (NHL) treated with targeted drugs and laboratory-confirmed COVID-19 diagnosed between February 2020 and January 2022. Median follow-up was 70.5 days (IQR 0-609). Most used targeted drugs were Bruton-kinase inhibitors (BKIs) (N= 201, 55%), anti-CD20 other than rituximab (N=61, 16%), BCL2 inhibitors (N=33, 9%) and lenalidomide (N=28, 8%).Only 16.2% of the patients were vaccinated with 2 or more doses of vaccine at the onset of COVID-19. Mortality was 24% (89/366) on day 30 and 36%(134/366) on the last day of follow-up. Age >75 years (p, EPICOVIDEHA has received funds from Optics COMMITTM (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States (Project 2020-8223).

Published
2022
Full Text
View/download PDF

2. Aplicació de la citogenètica convencional i la hibridació in situ a l'estudi de síndromes limfoproliferatives cròniques B

Author

Egozcue, Josep, Solé Ristol, Francesc, Espinet i Solà, Blanca, Egozcue, Josep, Solé Ristol, Francesc, and Espinet i Solà, Blanca

Abstract

Descripció del recurs: 26 febrer 2002, Titól obtingut de la portada digitalitzada, Les síndromes limfoproliferatives cròniques B (SLPC-B) són un grup divers de malalties que tenen en comú la proliferació neoplàsica i acumulació de cèl.lules limfoides de tipus B de tipus madur. Dins d'aquest grup, distingim bàsicament les leucèmies i els limfomes. El diagnòstic de les SLPC-B amb expressió leucèmica es basa en l'estudi integrat de la morfologia i l'immunofenotip de les cèl.lules leucèmiques, així com de les característiques citogenètiques i moleculars. Existeixen una sèrie d'entitats que poden ser confoses fàcilment i requereixen un estudi exhaustiu que permeti la seva classificació correcta. En el present treball s'analitzen tres d'aquestes entitats, la Leucèmia Limfàtica Crònica B atípica (LLC-Ba), el Limfoma de Cèl.lules del Mantell (LCM) i el Limfoma Esplènic de la Zona Marginal (LEZM) amb la intenció de trobar marcadors citogenètics que permetin separar-les, de manera que sigui possible establir un diagnòstic diferencial amb certesa. També es fa esment de la limfocitosi B Policlonal Persistent (LBPP). S'han estudiat 27 LLC-Ba, 13 LCM, 19 LEZM i 1 LBPP amb tècniques de citogenètica convencional i hibridació in situ, amb sondes centromèriques pels cromosomes 3, 12, 17 i 18, de locus específic per les regions 13q14 i 17p13 i de pintat cromosòmic. Entre les LLC-Ba, un 37% han presentat alteracions citogenètiques i l'alteració citogenètica més freqüent ha estat la trisomia 12 (63%), mentre que les delecions de 13q14 i 17p13 s'han detectat en % molt baix. Respecte els LCM, el 77% han presentat alteracions citogenètiques i dins d'aquests, en un 70% s'ha detectat la t(11;14)(q13;q32), alteració citogenètica característica d'aquesta entitat. Altres cromosomes implicats han estat: 1, 2, 9, 13 i 17 en forma d'alteracions estructurals principalment. No s'ha detectat la presència de trisomia 12 en cap pacient. En els LEZM, un 58% han presentat un cariotip alterat. Els cromosomes més freqüentment implicats han estat: 1, 3, 7, 8 i 14. Dels estudis inclosos en, B-cell lymphoproliferative disorders (BCLPD) constitute a group of pathologies in which mature B cells proliferate and accumulate in different tissues. Among BCLPD, leukaemic and lymphomatous diseases can be distinguished. In the present work, BCLPD with leukaemic expression are studied, taking into account at the same time morphologic, immunophenotypic, cytogenetic and molecular data. It is remarkable that the diagnosis of some BCLPD with leukaemic expression can be difficult because of some similar characteristics. In these cases, an exhaustive study will be required to a correct classification. In this thesis, three different entities would be analyzed: atypical B-cell lymphocytic leukaemia (aCLL), mantle cell lymphoma (MCL) and splenic marginal zone B-cell lymphoma (SMZBCL). The aim of the present study was to study the above mentioned entities by means of conventional cytogenetics and in situ hybridization techniques to analyze if different cytogenetic markers could be identified to establish a differential diagnosis among them. In addition, persistent polyclonal B-cell lymphocytosis (PPBL) was included in the study. Twenty seven aCLL, 13 MCL, 19 SMZBCL and 1 (PPBL) were studied cytogenetically and using in situ hybridization probes for centromeric regions of chromosomes 3, 12, 17 and 18, and for specific locus 13q14 (Rb) and 17p13 (p53). Among aCLL, 37% presented cytogenetic aberrations, being trisomy 12 the most frequent abnormality (63%), besides, 13q14 and 17p13 deletions were found in low percentage. Regarding MCL, chromosomal aberrations were found in 77% of patients, and among them, 70% presented a t(11;14)(q13;q32). Other affected chromosomes were 1, 2, 9, 13 and 17. No patient presented trisomy 12. In SMZBCL group, an abnormal karyotype was found in 58% of patients. The most frequently involved chromosomes were 1, 3, 7, 8 and 14. The most frequent structural abnormalities associated to SMZBCL were +3q and del(7q). No case presented +12, nor t(11;14)(q1

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results